RLY-4008
FGFR2-altered solid tumors (e.g., cholangiocarcinoma)
Key Facts
Indication
FGFR2-altered solid tumors (e.g., cholangiocarcinoma)
Phase
Phase 1/2
Status
Active
Company
About Relay Therapeutics
Relay Therapeutics is a clinical-stage biotech company founded in 2016 with a mission to transform drug discovery by targeting protein dynamics. Its core achievement is the development of the Dynamo™ platform, which integrates computational and experimental biology to identify novel therapeutic mechanisms. The company's strategy is to leverage this platform to create highly selective small molecule drugs for precision oncology, with its lead candidate, RLY-4008, in pivotal development for FGFR2-altered cancers. Relay is publicly traded and aims to validate its motion-based drug design approach through clinical success.
View full company profile